Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: A case series

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Kutoh, Eiji ^a,b  

^a Biomedical Center   (Japan)

^b Gyoda General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; BIPHASIC INSULIN; C PEPTIDE; CANDESARTAN; GLUCAGON; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; LANTAS; METFORMIN; MIGLITOL; NOVORAPID 30 MIX; SITAGLIPTIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CASE REPORT; DIABETIC KETOACIDOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 79953068028     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-117     Document Type: Article

References (10)

1. Incretin-based therapies for type 2 diabetes mellitus. JA Lovshin DJ Drucker, Nat Rev Endocrinol 2009 5 262 269 10.1038/nrendo.2009.48 19444259
2. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. JA Davidson, Cleve Clin J Med 2009 76 Suppl 5 28 S38 10.3949/ccjm.76.s5.05 19952301
3. Incretin and incretin-based therapies. N Harada N Inagaki, Nippon Rinsho 2010 68 931 942 20446595
4. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. T Vilsbøll J Rosenstock H Yki-Järvinen WT Cefalu Y Chen E Luo B Musser PJ Andryuk Y Ling KD Kaufman JM Amatruda SS Engel L Katz, Diabetes Obes Metab 2010 12 167 177 20092585
5. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. T Nagakura N Yasuda K Yamazaki H Ikuta I Tanaka, Metabolism 2003 52 81 86 10.1053/meta.2003.50014 12524666
6. Time for testing incretin therapies in early type 1 diabetes? E Bosi, J Clin Endocrinol Metab 2010 95 2607 2609 10.1210/jc.2009-2741 20525907
7. A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidence. A Imagawa T Hanafusa J Miyagawa Y Matsuzawa, Ann Med 2000 32 539 543 10.3109/07853890008998833 11127931
8. Effect of glucagon-like peptide-1 on - and -cell function in C-peptide-negative type 1 diabetic patients. U Kielgast M Asmar S Madsbad JJ Holst, J Clin Endocrinol Metab 2010 95 2492 2496 10.1210/jc.2009-2440 20207828
9. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus. AN Paisley MW Savage PG Wiles, Diabet Med 2009 26 935 938 10.1111/j.1464-5491.2009.02789.x 19719716
10. Incretin-based therapies in type 2 diabetes mellitus. CW Chia JM Egan, J Clin Endocrinol Metab 2008 93 3703 3716 10.1210/jc.2007-2109 18628530